



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## HDAC-IN-72

<b>Cat. No.:</b>	HY-162487
<b>CAS No.:</b>	763066-77-9
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>21</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	359.42
<b>Target:</b>	HDAC
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	HDAC-IN-72 (compound 7j) is the most potent HDAC1 (IC <sub>50</sub> =0.65 ± 0.07 μM), HDAC2 (IC <sub>50</sub> =0.78 ± 0.02 μM), HDAC3 (IC <sub>50</sub> =1.70 ± 0.1 μM) inhibitor and antiproliferative compound. HDAC-IN-72 can be used for breast cancer research <sup>[1]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	HDAC1 0.65 μM (IC <sub>50</sub> )	HDAC2 0.78 μM (IC <sub>50</sub> )	HDAC3 1.70 μM (IC <sub>50</sub> )
<b>In Vitro</b>	HDAC-IN-72 (0.1-50 μM, 48 h) shows good anti-proliferative activity against MCF-7 (IC <sub>50</sub> =0.83 ± 1.41 μM) and T47D (IC <sub>50</sub> =1.4 ± 1.85 μM) cell lines <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

### REFERENCES

[1]. Cheshmazar N, et al. Key structural requirements of benzamide derivatives for histone deacetylase inhibition: design, synthesis and biological evaluation[J]. Future Medicinal Chemistry, 2024 (0).

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA